IBDEI2D2 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40037,1,2,0)
 ;;=2^VALVULOPLASTY TRICUSPID w/o RING INSERT
 ;;^UTILITY(U,$J,358.3,40037,1,4,0)
 ;;=4^33463
 ;;^UTILITY(U,$J,358.3,40038,0)
 ;;=33464^^155^1944^11^^^^1
 ;;^UTILITY(U,$J,358.3,40038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40038,1,2,0)
 ;;=2^VALVULOPLASTY TRICUSPID w/ RING INSERT
 ;;^UTILITY(U,$J,358.3,40038,1,4,0)
 ;;=4^33464
 ;;^UTILITY(U,$J,358.3,40039,0)
 ;;=33510^^155^1944^2^^^^1
 ;;^UTILITY(U,$J,358.3,40039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40039,1,2,0)
 ;;=2^CABG VEIN SINGLE
 ;;^UTILITY(U,$J,358.3,40039,1,4,0)
 ;;=4^33510
 ;;^UTILITY(U,$J,358.3,40040,0)
 ;;=33641^^155^1944^6^^^^1
 ;;^UTILITY(U,$J,358.3,40040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40040,1,2,0)
 ;;=2^REPAIR HEART SEPTUM DEFECT
 ;;^UTILITY(U,$J,358.3,40040,1,4,0)
 ;;=4^33641
 ;;^UTILITY(U,$J,358.3,40041,0)
 ;;=35216^^155^1944^4^^^^1
 ;;^UTILITY(U,$J,358.3,40041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40041,1,2,0)
 ;;=2^RPR BLD VESSEL,DIRECT,INTRATHOR W/O BYPASS
 ;;^UTILITY(U,$J,358.3,40041,1,4,0)
 ;;=4^35216
 ;;^UTILITY(U,$J,358.3,40042,0)
 ;;=35276^^155^1944^5^^^^1
 ;;^UTILITY(U,$J,358.3,40042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40042,1,2,0)
 ;;=2^RPR BLD VESSEL,W/ GRAFT OTH THAN VEIN
 ;;^UTILITY(U,$J,358.3,40042,1,4,0)
 ;;=4^35276
 ;;^UTILITY(U,$J,358.3,40043,0)
 ;;=35685^^155^1944^1^^^^1
 ;;^UTILITY(U,$J,358.3,40043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40043,1,2,0)
 ;;=2^BYPASS GRAFT PATENCY/PATCH
 ;;^UTILITY(U,$J,358.3,40043,1,4,0)
 ;;=4^35685
 ;;^UTILITY(U,$J,358.3,40044,0)
 ;;=99415^^155^1945^1^^^^1
 ;;^UTILITY(U,$J,358.3,40044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40044,1,2,0)
 ;;=2^PROLONGED SVS W/ PT,1ST HR
 ;;^UTILITY(U,$J,358.3,40044,1,4,0)
 ;;=4^99415
 ;;^UTILITY(U,$J,358.3,40045,0)
 ;;=99416^^155^1945^2^^^^1
 ;;^UTILITY(U,$J,358.3,40045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40045,1,2,0)
 ;;=2^PROLONGED SVS,EA ADDL 30 MIN
 ;;^UTILITY(U,$J,358.3,40045,1,4,0)
 ;;=4^99416
 ;;^UTILITY(U,$J,358.3,40046,0)
 ;;=I27.9^^156^1946^1
 ;;^UTILITY(U,$J,358.3,40046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40046,1,3,0)
 ;;=3^Pulmonary heart disease, unspecified
 ;;^UTILITY(U,$J,358.3,40046,1,4,0)
 ;;=4^I27.9
 ;;^UTILITY(U,$J,358.3,40046,2)
 ;;=^5007154
 ;;^UTILITY(U,$J,358.3,40047,0)
 ;;=D61.09^^156^1947^4
 ;;^UTILITY(U,$J,358.3,40047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40047,1,3,0)
 ;;=3^Constitutional aplastic anemia NEC
 ;;^UTILITY(U,$J,358.3,40047,1,4,0)
 ;;=4^D61.09
 ;;^UTILITY(U,$J,358.3,40047,2)
 ;;=^334036
 ;;^UTILITY(U,$J,358.3,40048,0)
 ;;=D61.810^^156^1947^1
 ;;^UTILITY(U,$J,358.3,40048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40048,1,3,0)
 ;;=3^Antineoplastic chemotherapy induced pancytopenia
 ;;^UTILITY(U,$J,358.3,40048,1,4,0)
 ;;=4^D61.810
 ;;^UTILITY(U,$J,358.3,40048,2)
 ;;=^5002339
 ;;^UTILITY(U,$J,358.3,40049,0)
 ;;=D61.2^^156^1947^2
 ;;^UTILITY(U,$J,358.3,40049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40049,1,3,0)
 ;;=3^Aplastic anemia due to other external agents
 ;;^UTILITY(U,$J,358.3,40049,1,4,0)
 ;;=4^D61.2
 ;;^UTILITY(U,$J,358.3,40049,2)
 ;;=^5002337
 ;;^UTILITY(U,$J,358.3,40050,0)
 ;;=D61.1^^156^1947^5
 ;;^UTILITY(U,$J,358.3,40050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40050,1,3,0)
 ;;=3^Drug-induced aplastic anemia
 ;;^UTILITY(U,$J,358.3,40050,1,4,0)
 ;;=4^D61.1
 ;;^UTILITY(U,$J,358.3,40050,2)
 ;;=^5002336
 ;;^UTILITY(U,$J,358.3,40051,0)
 ;;=D61.89^^156^1947^3
 ;;^UTILITY(U,$J,358.3,40051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40051,1,3,0)
 ;;=3^Aplastic anemias and other bone marrow failure syndromes NEC
